Richard Marsden, chief executive at Synairgen (LON:SNG) discusses the further positive data from its LOXL2 inhibitor programme against the lung disease IPF.
Synairgen's chief hails exciting IPF data from LOXL2 inhibitor programme
Quick facts: Synairgen PLC
Price: 46 GBX
Market Cap: £50.34 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE